Lamivudine Pellets

(Product under development)
Lamivudine PelletsLamivudine (2',3'-dideoxy-3'-thiacytidine, commonly called 3TC) is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).

It is marketed by GlaxoSmithKline with the brand names Zeffix, Heptovir, Epivir, and Epivir-HBV.

Lamivudine has been used for treatment of chronic hepatitis B at a lower dose than for treatment of HIV. It improves the seroconversion of e-antigen positive hepatitis B and also improves histology staging of the liver.

Long term use of lamivudine unfortunately leads to emergence of a resistant hepatitis B virus (YMDD) mutant. Despite this, lamivudine is still used widely as it is well tolerated.

Availble Form:
Lamivudine Pellets
Lamivudine Granules

Umang Pharmatech equipments used for production of Lamivudine Pellets:
Drug Layering, Fluid Bed Dryer, Fluid Bed Coater, Sifter & Blender, Extruder and Twin spheronizer.

Lamivudine Pellets
Systematic (IUPAC) Name
Lamivudine Pellets
Lamivudine Pellets
Chemical data
CAS number : 134678-17-4
ATC code : J05AF05
PubChem : CID 73339
DrugBank : APRD00681
ChemSpider : 66068
UNII : 2T8Q726O95
KEGG : D00353
Synonyms : L-2',3'-dideoxy-3'-thiacytidine
Formula : C8H11N3O3S
Mol. mass : 229.26 g/mol

* All transactions are carried out in conformity with patent laws applicable in the user country. Active pharmaceutical ingredients or formulations thereof will not be supplied in countries where the same is under patent protection except as and if permitted under law of the country for research and development purposes only.
Extruder Spheronizer Email Us Umang Pharmatech